minoxidil / Generic mfg. - LARVOL DELTA

Pediatric alopecia universalis with poliosis post-psychosocial stress: a case report on methotrexate and adjunctive management. (PubMed, Acta Dermatovenerol Alp Pannonica Adriat) - "Initial treatment included topical clobetasol propionate 0.05% for 6 months, topical minoxidil 5% for 12 months, and oral vitamin D supplementation for 6 months, with minimal response. This case highlights psychosocial stress as a potential contributor in pediatric AU and supports a multidisciplinary approach. Methotrexate was effective and well tolerated, and poliosis may be a marker of follicular recovery."

Journal • Alopecia • Immunology • Pediatrics

Efficacy and Safety of Platelet-Rich Plasma Versus Topical Minoxidil in Androgenetic Alopecia: A Systematic Review. (PubMed, Cureus) - "Single-agent regimens provide partial responses without clear overall dominance. Adding monthly PRP injections to daily 5% minoxidil demonstrates promising comparative efficacy for vertex density restoration, though further standardized trials are warranted."

Journal • Review • Alopecia • Immunology

Radiofrequency Microporation Enhances Topical Minoxidil Delivery and Hair Regeneration in Androgenetic Alopecia. (PubMed, Pharmaceutics) - " RF microporation creates transient microchannels that enhance cutaneous MNX delivery and improve hair-regrowth efficacy. Importantly, RF-assisted topical administration maintained substantially lower systemic exposure than oral administration, supporting its potential as a needle-free strategy for topical AGA therapy and further translational evaluation."

Journal • Alopecia • Immunology

Androgenetic alopecia drugs and male infertility: Evidence from pharmacovigilance and testicular transcriptomics. (PubMed, PLoS One) - "This study systematically evaluated associations between AGA drugs and male infertility using real-world pharmacovigilance data and integrated bioinformatic analyses. The HIF1A-related transcriptomic findings provide a hypothesis-generating biological context for male infertility but do not establish a shared or drug-specific mechanism linking the three medications to infertility. The pharmacovigilance findings indicate reporting signals rather than incidence or causality."

Adverse events • Journal • Alopecia • Immunology • Infertility • Sexual Disorders • FGF • HIF1A

Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "This case adds to emerging evidence that dupilumab may be considered in carefully selected pediatric patients with severe, treatment-refractory AA and features suggestive of type 2 immune involvement. Because minoxidil was continued concomitantly, baseline inflammatory activity was limited, and spontaneous regrowth cannot be excluded, the clinical improvement cannot be attributed to dupilumab alone."

Journal • Alopecia • Dermatology • Immunology • Inflammation • Pediatrics

Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults. (PubMed, JAMA Dermatol) - "Oral Janus kinase inhibitors represented the primary, long-term therapy for all patients, with dupilumab as an alternative option for patients with comorbid atopy. Supplemental treatments included oral and topical minoxidil; intralesional, oral, and high-potency topical corticosteroids; and topical Janus kinase inhibitors and prostaglandins, with body site-specific indications...Additional high-quality investigations are needed to establish the efficacy of existing therapies in subpopulations and enable head-to-head comparisons of new and existing interventions. These recommendations are not indicated for children, pregnant patients, patients with mild to moderate disease, or those with underlying comorbidities; additional research is needed to inform treatment guidelines for these specific patient populations."

Clinical • Journal • Alopecia • Immunology • Pediatrics

Oral medications for hair loss in the elderly (EADV 2026) - "This includes low-dose oral minoxidil, finasteride, dutasteride, spironolactone, hydroxychloroquine and JAK inhibitors. Learning Objectives After this presentation, participants should be able to: Select suitable oral treatments for androgenetic alopecia, frontal fibrosing alopecia and alopecia areata.Assess cardiovascular, renal, thrombotic, infectious and oncological risks before treatment. Apply recent recommendations on low-dose oral minoxidil and JAK inhibitors."

Clinical • Alopecia • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Lichen Planus • Nephrology • Renal Disease • Thrombosis

Improved transcutaneous delivery of cetirizine hydrochloride for the treatment of post-chemotherapy alopecia: Poke and emulgel approach. (PubMed, Pak J Pharm Sci) - "The prepared cetirizine HCl-loaded emulgel and microneedle combination may be a promising approach to treating chemotherapy-induced alopecia."

Journal • Alopecia • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Oncology

ROS-Scavenging Hyperbranched Polymer Dot Nanozymes Combined with Fractional CO2 Laser Microchannels for Hair Follicle Regeneration. (PubMed, Int J Nanomedicine) - "Laser microchannels act as both delivery portals and regenerative triggers, while HPD scavenges post-injury reactive oxygen species and sustains Wnt/β-catenin activation, producing a greater-than-additive acceleration of hair follicle regeneration exceeding minoxidil. This reflects activation and accelerated growth of existing follicles rather than de novo neogenesis, and offers a drug-free platform for regenerative dermatology."

Journal • Aesthetic Medicine • Dermatology

Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice. (PubMed, Clin Dermatol) - "Management strategies include nutritional optimization with protein targets of 1.2-2.0 g/kg/day based on adjusted body weight, patient counseling on the anticipated time course of hair shedding, and pharmacologic options including low-dose oral minoxidil. The hair loss profile of GLP-1 RAs is compared with that of bariatric surgery, where pooled incidence ranges from 47%-57%. Practical guidance for the clinician is provided throughout."

Journal • Alopecia • Immunology

Oral minoxidil enhances early response to baricitinib in moderate-to-severe alopecia areata. A retrospective study of 59 patients. (EADV 2026) - No abstract available

Retrospective data • Alopecia • Immunology

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial (EADV 2026) - No abstract available

Clinical

Early Intervention of 5% Minoxidil Usage Yields Improved Hair Regrowth in Male Androgenetic Alopecia: The Effects of Age and Stage (EADV 2026) - No abstract available

Alopecia • Immunology

Safety of low dose oral minoxidil in healthy South Asian adult population (EADV 2026) - No abstract available

Clinical

Adjunctive Non-Ablative Fractional 1550-nm Diode Laser With 2% Topical Minoxidil for Female Pattern Hair Loss: A Split-Scalp Case Series in Asian Women With Fitzpatrick Skin Types IV–V (EADV 2026) - No abstract available

Clinical • Alopecia

Cardiovascular Safety and Efficacy of Low-Dose Oral Minoxidil 5 mg Daily in Men with Androgenetic Alopecia: An Open-Label, Prospective Pilot Study with Echocardiographic Evaluation (MAACD Study) (EADV 2026) - No abstract available

Clinical • Alopecia • Cardiovascular • Immunology

Hair regrowth in female androgenetic alopecia combining microneedling-assisted delivery of minoxidil and dutasteride with topical minoxidil and oral spironolactone (EADV 2026) - No abstract available

Alopecia • Immunology

Comparison of effectiveness and safety of low-dose oral minoxidil (1.25 mg) versus topical 5% minoxidil in male androgenetic alopecia: a randomized open-label pilot study (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Crowning Glory: Safety and efficacy of 1.25 mg versus 2.5 mg oral minoxidil in male androgenic alopecia (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Comparison Of Efficacy Between 5% Minoxidil And 5% Procapil In Patients With Androgenetic Alopecia (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Cardiovascular Safety of Oral Minoxidil Use in Dermatologic Patients: A Systematic Review and Meta-Analysis (EADV 2026) - No abstract available

Retrospective data • Review • Cardiovascular

Efficacy and Safety of Low-Dose Oral versus Topical Minoxidil in Androgenetic Alopecia: A Double-Blind, Double-Dummy Randomized Controlled Trial in a South Asian Population (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Evaluation of the Efficacy of Exosome versus Platelet-Rich Plasma or Minoxidil in Treatment of Androgenetic Alopecia (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Raynaud's phenomenon associated with concomitant use of topical minoxidil (EADV 2026) - No abstract available

Cardiovascular • Rheumatology

Evaluation of the Sulfotransferase activity in Androgenetic alopecia patients using genotyping of SULT1A1 to predict the individual's response to oral minoxidil. (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology • SULT1A1